Compare SNA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNA | RPRX |
|---|---|---|
| Founded | 1920 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 16.7B |
| IPO Year | N/A | 2020 |
| Metric | SNA | RPRX |
|---|---|---|
| Price | $369.87 | $44.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $361.00 | $47.75 |
| AVG Volume (30 Days) | 342.2K | ★ 3.9M |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.63% | 2.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 19.19 | 1.75 |
| Revenue | ★ $5,156,100,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $38.81 |
| Revenue Next Year | $3.42 | $2.26 |
| P/E Ratio | ★ $19.32 | $25.18 |
| Revenue Growth | 0.93 | ★ 3.70 |
| 52 Week Low | $289.81 | $29.66 |
| 52 Week High | $388.96 | $44.36 |
| Indicator | SNA | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 78.82 |
| Support Level | $364.01 | $40.16 |
| Resistance Level | $388.96 | $44.36 |
| Average True Range (ATR) | 7.89 | 0.66 |
| MACD | -0.36 | 0.38 |
| Stochastic Oscillator | 36.01 | 98.45 |
Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars but having expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business that is focused on repair facilities serving other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly and also offers substantial diagnostic solutions to aid repairs. The company's finance arm provides financing to franchisees to run their operations, as well as underwriting end customer purchases.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.